According to Takeda Pharmaceutical's latest financial reports the company has a price-to-book ratio of 0.8657.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.9418 | -8.33% |
2022-12-31 | 1.03 | 11.47% |
2021-12-31 | 0.9217 | -27.15% |
2020-12-31 | 1.27 | -8.56% |
2019-12-31 | 1.38 | -2.36% |
2018-12-31 | 1.42 | -39.4% |
2017-12-31 | 2.34 | 25.64% |
2016-12-31 | 1.86 | -15.57% |
2015-12-31 | 2.20 | 43.79% |
2014-12-31 | 1.53 | -1.26% |
2013-12-31 | 1.55 | 8.32% |
2012-12-31 | 1.43 | 5.58% |
2011-12-31 | 1.36 | -9.3% |
2010-12-31 | 1.50 | 4.62% |
2009-12-31 | 1.43 | -33.87% |
2008-12-31 | 2.16 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.20 | 501.17% | ๐บ๐ธ USA |
Novartis NVS | 4.32 | 399.41% | ๐จ๐ญ Switzerland |
Pfizer PFE | 1.67 | 92.44% | ๐บ๐ธ USA |
Amgen AMGN | 23.5 | 2,614.23% | ๐บ๐ธ USA |
Sanofi SNY | 1.50 | 73.15% | ๐ซ๐ท France |
Merck MRK | 8.80 | 916.29% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | 5.13 | 492.74% | ๐ฌ๐ง UK |
Seagen
SGEN | 16.9 | 1,854.54% | ๐บ๐ธ USA |
Dr. Reddy's RDY | 3.83 | 342.54% | ๐ฎ๐ณ India |